VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma

Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrates superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter